ImmunoGen aims to conduct Phase I study of lymphoma drug

09/25/2011 | American City Business Journals

ImmunoGen submitted an application to the FDA seeking approval to launch a Phase I trial of IMGN529, a drug candidate for patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company said the drug contains an antibody that facilitates death of tumor cells by delivering anti-cancer agent DM1 directly to B cells.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN